scholarly journals Neurocognitive Impairment after Hematopoietic Stem Cell Transplant for Hematologic Malignancies: Phenotype and Mechanisms

2021 ◽  
Author(s):  
Rebecca Harrison ◽  
Noha Sharafeldin ◽  
Jennie L Rexer ◽  
Brennan Streck ◽  
Melissa Petersen ◽  
...  
Keyword(s):  
Stem Cell ◽  
Hematopoietic Stem Cell ◽  
Hematopoietic Stem Cell Transplant ◽  
Stem Cell Transplant ◽  
Hematologic Malignancies ◽  
Neurocognitive Impairment ◽  
Cell Transplant ◽  
Hematopoietic Stem

scholarly journals Immune Therapies for Hematologic Malignancies

Cancers ◽  
2021 ◽  
Vol 13 (2) ◽  
pp. 295
Author(s):  
Matthew J. Olnes
Keyword(s):  
Stem Cell ◽  
Hematopoietic Stem Cell ◽  
Hematopoietic Stem Cell Transplant ◽  
Stem Cell Transplant ◽  
Hematologic Malignancies ◽  
Cell Transplant ◽  
Hematopoietic Stem ◽  
Immune Therapies

The era of immunotherapy for hematologic malignancies began with the first allogeneic hematopoietic stem cell transplant (HSCT) study published by E [...]

scholarly journals EXPRESS: Successful treatment of pulmonary hypertension following hematopoietic stem cell transplant with a single oral tadalafil : A case report

2021 ◽  
pp. 204589402110277
Author(s):  
Toshikazu D Tanaka ◽  
David C Ishizawar ◽  
Takeshi Saito ◽  
Akira Yoshii ◽  
Michihiro Yoshimura
Keyword(s):  
Stem Cell ◽  
Hematopoietic Stem Cell ◽  
Hematopoietic Stem Cell Transplant ◽  
Stem Cell Transplant ◽  
Lymphoblastic Leukemia ◽  
Hematologic Malignancies ◽  
Pulmonary Vascular Disease ◽  
Cell Transplant ◽  
Hematopoietic Stem ◽  
Pulmonary Vasodilator

A 46-year-old man who had undergone hematopoietic stem cell transplant (HSCT) twice because of acute lymphoblastic leukemia with recurrence presented with dyspnea, leading to a diagnosis of pulmonary arterial hypertension (PAH) which was quickly and effectively treated with the PDE-5 inhibitor tadalafil. To our knowledge, PAH related to hematologic malignancies requiring HSCT is rarely reported. Importantly, the present case suggests that early diagnosis and treatment with a pulmonary vasodilator, such as tadalafil, can greatly decrease pulmonary vascular resistance in patients with severe PAH after HSCT and can then improve other symptoms. Accordingly, pulmonary vascular disease should be considered if respiratory symptoms develop following HSCT, because treatment with pulmonary vasodilator may lead to significant improvement in PAH.

Sign in / Sign up

Export Citation Format

Share Document